My Cart [ 0 ]
Home > Cell Biology > Stable Cell Lines > NovoSeven Biosimilar Stable Cell Line

NovoSeven Biosimilar Stable Cell Line

Activated Eptacog Alfa, Recombinant Coagulation Factor VIIa Protein

Catalog No. Product Name Size List Price (US$) Quantity
C016 NovoSeven Biosimilar Stable Cell Line 1 package Request

NovoSeven, recombinant human factor VIIa, is used for uncontrolled bleeding in hemophilia patients (with Factor VII, VIII or IX deficiency). Factor VII (FVII) is one of the proteins that causes blood to clot in the coagulation cascade. The main role of FVII is to initiate the process of coagulation in conjunction with tissue factor (TF/factor III). Upon vessel injury, tissue factor is exposed to the blood and circulating factor VII. Once bound to TF, FVII is activated to FVIIa (blood-coagulation factor VIIa, activated blood coagulation factor VII, FVIIa, or proconvertin) by different proteases.

C016: NovoSeven Biosimilar Stable Cell Line (CHO)

The yield of NovoSeven biosimilar from the CHO stable cell line was above 30 mg/L in a 1000 liter manufacturing.

The NovoSeven biosimilar stable cell line alone can be transfered alone or together with the technology of process development and/or antibody purification.

Syd Labs also provides the following clotting or coagulation-related biosimilar stable cell lines:
Advate / Kogenate Biosimilar Stable Cell Line (Factor VIII)
ReFacto Biosimilar Stable Cell Line (truncated Factor VIII)
BeneFIX Biosimilar Stable Cell Line (Factor IX)

Related Links

See our Privacy Policy